Assessing Trial Results for All Endpoints for Dara-KRd in Treatment of Multiple Myeloma

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the results for all of the trial endpoints assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma.

Pharmacy Times interviewed Luciano Costa, MD, PhD, associate director for clinical research at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, on his recent presentation at the American Society of Hematology Annual Meeting and Exposition 2021 on the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous transplantation, and minimal residual disease response-adapted consolidation and treatment cessation.

During this video, Costa discusses the trial results for all trial endpoints assessing Dara-KRd in the treatment of patients with newly diagnosed multiple myeloma, and what the trial results showed regarding meeting these endpoints.